Disclosure under Regulation 7(2)(b) of Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( SEBI (PIT) Regulations, 2015 )
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Six members of the Promoter and Promoter Group of Ind-Swift Laboratories received a total of 39,46,094 equity shares on August 25, 2025, pursuant to a Scheme of Amalgamation between Ind-Swift Limited (Transferor Company) and Ind-Swift Laboratories (Transferee Company). The scheme was approved by the NCLT Chandigarh Bench on July 17, 2025. The largest allottee was promoter Essix Biosciences Limited, which received 25,55,014 shares (valued at over Rs 25.55 crore), bringing its holding from 34.33% to 34.04% (slight dilution due to expanded share base). The remaining five allottees — S.R. Mehta, Sunita Jain, V.R. Mehta, Neera Mehta, and Gopal Munjal — each received between 2.3 lakh and 3.1 lakh shares. This is a routine insider trading disclosure filed to comply with SEBI PIT Regulations following the share allotment.
This is a non-cash, court-approved allotment linked to the amalgamation and does not involve any market buying or change in promoter control. Shareholders should note that the promoter group's overall shareholding percentage has slightly diluted due to the expanded capital base, but no material adverse impact on stock price is expected from this disclosure alone.